{
  "citations" : [],
  "guideline" : {
    "objCls" : "Guideline Annotation",
    "id" : "PA166288541",
    "name" : "Annotation of CPIC Guideline for fluoxetine and CYP2D6",
    "alternateDrugAvailable" : false,
    "cancerGenome" : false,
    "crossReferences" : [],
    "descriptiveVideoId" : "UWRTwdNT1ek",
    "dosingInformation" : false,
    "hasTestingInfo" : false,
    "history" : [
      {
        "id" : 1452065000,
        "date" : "2023-04-10T14:19:30.231-07:00",
        "description" : "added CPIC guideline publication",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1452506960,
        "date" : "2024-06-25T01:18:30.969-07:00",
        "description" : "Added video",
        "type" : "Update",
        "version" : 0
      }
    ],
    "literature" : [
      {"id":15143242,"title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants.","_sameAs":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564324","crossReferences":[{"id":1452680439,"resource":"PubMed Central","resourceId":"PMC10564324","_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564324"},{"id":1452064840,"resource":"PubMed","resourceId":"37032427","_url":"https://www.ncbi.nlm.nih.gov/pubmed/37032427"},{"id":1452064841,"resource":"DOI","resourceId":"10.1002/cpt.2903","_url":"http://dx.doi.org/10.1002%2Fcpt.2903"}],"objCls":"Literature","pubDate":"2023-07-01T00:00:00-07:00","terms":[{"id":1454108620,"resource":"ClinPGx Tags","term":"CPIC","termId":"pgkbTags:1454108620"},{"id":1451577480,"resource":"PGx Paper Types","term":"Implementation","termId":"pgxPaperTypes:1451577480"}],"type":"Literature"}
    ],
    "otherPrescribingGuidance" : false,
    "pediatric" : false,
    "recommendation" : false,
    "relatedAlleles" : [],
    "relatedChemicals" : [
      {
        "objCls" : "Chemical",
        "id" : "PA449673",
        "name" : "fluoxetine",
        "version" : 21
      }
    ],
    "relatedGenes" : [
      {
        "objCls" : "Gene",
        "id" : "PA128",
        "symbol" : "CYP2D6",
        "name" : "cytochrome P450 family 2 subfamily D member 6",
        "version" : 7891
      }
    ],
    "source" : "CPIC",
    "summaryMarkdown" : {
      "id" : 1452007420,
      "html" : "<p>There are currently no recommendations for dosing of fluoxetine based on <em>CYP2D6</em>  genotypes.</p>\n",
      "version" : 1
    },
    "terms" : [],
    "textMarkdown" : {
      "id" : 1452007400,
      "html" : "<p>This annotation is based on the <a rel=\"noopener noreferrer\" href=\"https://cpicpgx.org/guidelines/cpic-guideline-for-ssri-and-snri-antidepressants/\" target=\"_blank\">CPIC&reg; guideline for <em>CYP2D6</em>, <em>CYP2C19</em>, <em>CYP2B6</em>, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants</a>.</p>\n<h3 id=\"february-2023\">February 2023</h3>\n<p>The authors of the <a rel=\"noopener noreferrer\" href=\"https://cpicpgx.org/guidelines/cpic-guideline-for-ssri-and-snri-antidepressants/\" target=\"_blank\">CPIC&reg; guideline for <em>CYP2D6</em>, <em>CYP2C19</em>, <em>CYP2B6</em>, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants</a> evaluated the available evidence for the use of fluoxetine in patients carrying <em>CYP2D6</em> and <em>CYP2C19</em> variants.</p>\n<ul>\n<li>\n<p>Excerpts from the guideline:</p>\n<ul>\n<li>&quot;CYP2D6 UMs or PMs have been demonstrated to possess significantly different parent to metabolite ratios (Table S1) but the sum total of fluoxetine plus norfluoxetine plasma concentrations may not vary significantly by CYP2D6 metabolizer groups (43).&quot;</li>\n<li>&quot;Little data are available describing how CYP2D6 phenotype status influences the sum total of fluoxetine plus norfluoxetine concentrations over time or if an imbalance between fluoxetine and norfluoxetine concentrations caused by CYP2D6 phenotype status affects patient outcomes or safety. Therefore, no gene-based dosing recommendations are provided for fluoxetine.&quot;</li>\n</ul>\n</li>\n<li>\n<p>Download and read:</p>\n<ul>\n<li><a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/data/guideline/publication/serotonin_reuptake_inhibitor_antidepressants/2023/37032427.pdf\" target=\"_blank\">CPIC&reg; Guideline for for <em>CYP2D6</em>, <em>CYP2C19</em>, <em>CYP2B6</em>, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants</a></li>\n<li><a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/data/guideline/publication/serotonin_reuptake_inhibitor_antidepressants/2023/37032427-supplement.pdf\" target=\"_blank\">2023 supplement</a></li>\n</ul>\n</li>\n</ul>\n<h3 id=\"table-1-dosing-recommendations-for-fluoxetine-based-on-cyp2d6-phenotype\">Table 1: Dosing recommendations for fluoxetine based on CYP2D6 phenotype</h3>\n<p><em>Adapted from Tables 1 and S6 of the guideline/supplement.</em></p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Phenotype</th>\n<th>Activity score<br/>range</th>\n<th>Activity score</th>\n<th>Examples</th>\n<th>Implications</th>\n<th>Therapeutic<br/>Recommendations</th>\n<th>Classification of<br/>recommendation<sup>a</sup></th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>CYP2D6 ultrarapid metabolizer</td>\n<td>&gt;2.25</td>\n<td>&gt;2.25</td>\n<td><em>*1/*1xN, *1/*2xN, *2/*2xN<sup>c</sup></em></td>\n<td>Increased metabolism of fluoxetine and decreased fluoxetine:norfluoxetine ratio as compared to normal metabolizers. There is a lack of evidence supporting the clinical impact of decreased fluoxetine:norfluoxetine ratio. The extent to which ultrarapid metabolizers phenoconvert to normal, intermediate, or poor metabolizers due to fluoxetine and norfluoxetine inhibition of CYP2D6 is unclear.</td>\n<td>No action recommended based on genotype for fluoxetine because of minimal evidence regarding the impact on efficacy or side effects.</td>\n<td>No recommendation</td>\n</tr>\n<tr>\n<td>CYP2D6 normal metabolizer</td>\n<td>1.25 &lt;= x &lt;= 2.25</td>\n<td>1.25<br/>1.5<br/>1.75<br/>2.0<br/>2.25</td>\n<td><em>*1/*10<br/>*1/*41, *1/*9<br/>*10/*41x3<br/>*1/*1, *1/*2<br/>*2x2/*10</em></td>\n<td>Normal metabolism. The extent to which normal metabolizers phenoconvert to intermediate or poor metabolizers due to fluoxetine and norfluoxetine inhibition of CYP2D6 is unclear.</td>\n<td>Initiate therapy with recommended starting dose.</td>\n<td>Strong</td>\n</tr>\n<tr>\n<td>CYP2D6 intermediate metabolizer</td>\n<td>0 &lt; x &lt; 1.25</td>\n<td>0.25<br/>0.5<br/>0.75<br/>1.0</td>\n<td>*4/*10<br/>*4/*41, *10/*10<br/>*10/*41<br/>*41/*41, *1/*5</td>\n<td>Decreased metabolism of fluoxetine and increased fluoxetine:norfluoxetine ratio but similar total active enantiomer concentrations compared to normal metabolizers. There is a lack of evidence supporting the clinical impact of increased fluoxetine:norfluoxetine ratio. The extent to which intermediate metabolizers phenoconvert to poor metabolizer due to fluoxetine and norfluoxetine inhibition of CYP2D6 is unclear.</td>\n<td>No action recommended based on genotype for fluoxetine because of minimal evidence regarding the impact on efficacy or side effects.</td>\n<td>No recommendation</td>\n</tr>\n<tr>\n<td>CYP2D6 poor metabolizer</td>\n<td>0</td>\n<td>0</td>\n<td><em>*3/*4, *4/*4, *5/*5, *5/*6</em></td>\n<td>Decreased metabolism of fluoxetine to active metabolites and greatly increased fluoxetine:norfluoxetine ratio but similar total active enantiomer concentrations compared to normal metabolizers. There is a lack of evidence supporting the clinical impact of increased fluoxetine:norfluoxetine ratio.</td>\n<td>No action recommended based on genotype for fluoxetine because of minimal evidence regarding the impact on efficacy or side effects.</td>\n<td>No recommendation</td>\n</tr>\n</tbody>\n</table>\n<p><sup>a</sup> Rating scheme described in Supplemental Materials.</p>\n",
      "version" : 0
    },
    "version" : 2
  }
}